Comparative Analysis of Bioactivity of the Russian-Made Antitumor Substances of the Nitrosourea Group
- Авторы: Bunyatyan N.1,2, Oborotova N.1,3, Nikolaeva L.1,3, Saprykina N.3, Borisova L.3, Kiseleva M.3, Prokof’ev A.1,2
-
Учреждения:
- I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation
- Research Center for Expert Evaluation of Medical Products, Ministry of Health of the Russian Federation
- N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
- Выпуск: Том 166, № 4 (2019)
- Страницы: 456-460
- Раздел: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/241099
- DOI: https://doi.org/10.1007/s10517-019-04371-w
- ID: 241099
Цитировать
Аннотация
We performed an in vivo comparative study of activity of three substances of the nitrosourea group produced in Russia. All substances demonstrated high antitumor activity against various solid and leukemic tumors. Aranosa significantly enhanced life duration in mice with leukemia (by 65-194%) and inhibited the growth of solid tumors (by 49-99.6%). Lisomustine and ormustine showed higher activity than aranose. Single administration of lisomustine increased life span of mice (by 22-114%) and resulted in cure of all animals in four models: lymphoblastic leukemia L-1210, lymphocytic leukemia P-388, Lewis lung carcinoma, and cervical cancer RShM-5. After ormustine treatment, full recovery was observed only in groups with lymphocytic leukemia P-388 and cervical cancer RShM-5. These findings attest to higher activity of lisomustine in the studied models.
Об авторах
N. Bunyatyan
I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation; Research Center for Expert Evaluation of Medical Products, Ministry of Health of the Russian Federation
Автор, ответственный за переписку.
Email: ndbun@mail.ru
Россия, Moscow; Moscow
N. Oborotova
I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation; N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: ndbun@mail.ru
Россия, Moscow; Moscow
L. Nikolaeva
I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation; N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: ndbun@mail.ru
Россия, Moscow; Moscow
N. Saprykina
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: ndbun@mail.ru
Россия, Moscow
L. Borisova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: ndbun@mail.ru
Россия, Moscow
M. Kiseleva
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: ndbun@mail.ru
Россия, Moscow
A. Prokof’ev
I. M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of the Russian Federation; Research Center for Expert Evaluation of Medical Products, Ministry of Health of the Russian Federation
Email: ndbun@mail.ru
Россия, Moscow; Moscow
![](/img/style/loading.gif)